ArticleESMO gastrointestinal oncology2024

Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis.

K Shimozaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.